FDA Approves Clinical Trial Application for SYH2059
SYH2095 tablets, a Class 1 chemical new drug co-developed by the Group and Hangzhou Innogate Pharma Co., Ltd., has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The Product is a novel, highly selective lysine acetyltransferase 6 (‘‘KAT6’’) inhibitor and belongs to a class of epigenetic anticancer drugs. The Product exerts its anti-tumor effects by inhibiting the acetylation of histone lysine, blocking open chromatin, and thereby regulating the cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.